ExodusPoint Capital Management LP cut its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 74.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,506 shares of the biopharmaceutical company's stock after selling 94,144 shares during the period. ExodusPoint Capital Management LP owned about 0.05% of Vanda Pharmaceuticals worth $151,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of VNDA. SG Americas Securities LLC boosted its holdings in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 5,459 shares in the last quarter. Brandywine Global Investment Management LLC raised its stake in Vanda Pharmaceuticals by 13.9% during the fourth quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company's stock worth $189,000 after acquiring an additional 4,820 shares in the last quarter. Verition Fund Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company's stock valued at $189,000 after acquiring an additional 2,927 shares during the period. Franklin Resources Inc. boosted its stake in shares of Vanda Pharmaceuticals by 8.8% in the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company's stock valued at $266,000 after purchasing an additional 4,449 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Vanda Pharmaceuticals by 1,184.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company's stock worth $292,000 after purchasing an additional 57,393 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several analysts have weighed in on VNDA shares. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, April 1st.
Check Out Our Latest Analysis on VNDA
Insider Activity
In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was acquired at an average cost of $4.46 per share, with a total value of $44,600.00. Following the completion of the purchase, the chief executive officer now directly owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. This trade represents a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have acquired 32,000 shares of company stock valued at $151,180. 8.90% of the stock is currently owned by insiders.
Vanda Pharmaceuticals Price Performance
Shares of VNDA stock traded down $0.04 during trading hours on Friday, reaching $4.33. 506,632 shares of the company were exchanged, compared to its average volume of 790,125. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.85 and a fifty-two week high of $6.75. The stock's fifty day moving average is $4.59 and its two-hundred day moving average is $4.68. The company has a market cap of $252.51 million, a price-to-earnings ratio of -13.53 and a beta of 0.72.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. On average, research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.
Vanda Pharmaceuticals Company Profile
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
